These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8728055)

  • 21. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Removal of gp160 induced bio-hazards for a safe AIDS vaccine candidate.
    Picard O; Bernard J; Lachgar A; Fall L; Carlotti M; Achour A; Carelli C; Salaun JJ; Mbika JP; Lurhuma Z
    Biomed Pharmacother; 1992; 46(8):353-7. PubMed ID: 1292645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current approaches to vaccination against human immunodeficiency viruses.
    Gluckman JC; Yagello M; Bahraoui E; Girard M
    Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
    [No Abstract]   [Full Text] [Related]  

  • 24. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
    Montefiori DC; Evans TG
    AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
    Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular immune response to HIV gp160 vaccine.
    Stricker RB; Goldberg B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 7914236
    [No Abstract]   [Full Text] [Related]  

  • 27. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.
    McElrath MJ; Corey L; Berger D; Hoffman MC; Klucking S; Dragavon J; Peterson E; Greenberg PD
    J Infect Dis; 1994 Jan; 169(1):41-7. PubMed ID: 8277196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA inoculation induces cross clade anti-HIV-1 responses.
    Wang B; Boyer J; Srikantan V; Ugen K; Agadjanian M; Merva M; Gilbert L; Dang K; McCallus D; Moelling K
    Ann N Y Acad Sci; 1995 Nov; 772():186-97. PubMed ID: 8546392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.
    Stanhope PE; Clements ML; Siliciano RF
    J Infect Dis; 1993 Jul; 168(1):92-100. PubMed ID: 8099941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
    Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
    J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Another reversal for the AIDS Vaccine Trial?
    Science; 1993 May; 260(5112):1227. PubMed ID: 8493562
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
    J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial results thwart HIV-vaccine hopes.
    McCarthy M
    Lancet; 1996 Apr; 347(9009):1173. PubMed ID: 8609757
    [No Abstract]   [Full Text] [Related]  

  • 37. Properties of an HIV 'vaccine'.
    Wahren B; Sandström E; Wigzell H
    Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1.
    Keay S; Tacket CO; Murphy JR; Handwerger BS
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1091-8. PubMed ID: 1503823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with gp160 in HIV.
    Oyaizu N; Chirmule N; Pahwa S
    N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
    [No Abstract]   [Full Text] [Related]  

  • 40. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.